Treatments involving glutaredoxins and similar agents
AssigneesUniversity of Vermont and State Agricultural College, Universiteit Maastricht
InventorsYvonne M. Janssen-Heininger, Niki Lea Reynaert, Vikas Anathy, Scott Aesif
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.
Claims16
A composition, comprising a glutaredoxin, wherein the glutaredoxin has an inactivated caspase cleavage site, wherein the inactivated caspase cleavage site comprises Glu-Phe-Val-Asp (SEQ ID NO:9).
A composition, comprising:
- a glutaredoxin wherein the glutaredoxin has an identity of greater than 90% with GRX in combination with a pharmaceutically acceptable carrier for pulmonary delivery, wherein glutaredoxin is GRX1, GRX2, GRX5, comprising an inactivated caspase cleavage site comprising Glu-Phe-Val-Asp (SEQ ID NO:9).
Dependencies are inferred from the claim text.